CU
Publicaties op Oncologisch.com
Durable responses upon short-term addition of targeted therapy to anti-PD1 in gevorderd melanoma patients: 5-year pro...
Neoadjuvant ipilimumab-nivolumab bij melanoom: OpACIN-neo overlevingsupdate
Locoregionaal melanoom: ESMO consensusaanbevelingen
Gemetastaseerd melanoom: ESMO consensusaanbevelingen